{"id":68837,"date":"2025-03-15T20:40:27","date_gmt":"2025-03-16T00:40:27","guid":{"rendered":"https:\/\/www.med.unc.edu\/medicine\/?p=68837"},"modified":"2025-03-19T09:48:06","modified_gmt":"2025-03-19T13:48:06","slug":"joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml","status":"publish","type":"post","link":"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/","title":{"rendered":"Joshua Zeidner, MD, Publishes “ENHANCE-2 Study” on Magrolimab and Azacitidine for TP53-Mutated AML."},"content":{"rendered":"
\"Joshua-zeidner\"
Joshua Zeidner, MD<\/figcaption><\/figure>\n

Joshua Zeidner, MD, an Associate Professor of Medicine and Chief of Leukemia Research, published a paper in the journal Blood. <\/em>Titled “Magrolimab plus azacitidine vs physician’s choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study,” <\/em>he\u00a0looked at a global randomized phase 3 study in acute myeloid leukemia (AML).<\/p>\n

This study examined patients with TP53-mutated AML who have an extremely poor prognosis without any known effective therapies. Historically, average overall survival is approximately 5-6 months in patients with newly diagnosed TP53-mutated AML. Magrolimab is an investigational monoclonal antibody targeting CD47 which promotes phagocytosis (or the eating and destruction) of cancer cells. In an early phase 1b study, the combination of azacitidine and magrolimab was demonstrated to be safe with very promising clinical activity in patients with newly diagnosed TP53-mutated AML with complete remission rates of 32% and average overall survival of 10 months (https:\/\/pubmed.ncbi.nlm.nih.gov\/37703506\/).<\/p>\n

These promising results led to the development of a global phase 3 clinical trial comparing two treatment options for newly diagnosed TP53-mutated AML. One group received azacitidine with the investigational drug magrolimab, while the other received a treatment chosen by their physician\u2014either azacitidine with venetoclax or intensive chemotherapy (7+3).<\/p>\n

In the planned comparison between azacitidine with magrolimab and azacitidine with venetoclax, 205 patients were randomly assigned to one of the two groups. However, an interim analysis led to the study being halted due to futility. Patients receiving azacitidine with magrolimab had an average overall survival of 4.4 months, compared to 6.6 months for those receiving azacitidine with venetoclax.<\/p>\n

This is the first published randomized trial for TP53-mutated AML, a patient group with a high need for new treatments. The results confirm the limited effectiveness of standard therapies for this population and provide a benchmark for future research.<\/p>\n

Read the full paper here.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Joshua Zeidner, MD, an Associate Professor of Medicine and Chief of Leukemia Research, published a paper in the journal Blood. Titled “Magrolimab plus azacitidine vs physician’s choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study,” he\u00a0looked at a global randomized phase 3 study in acute myeloid leukemia (AML). This study examined patients with TP53-mutated … Read more<\/a><\/p>\n","protected":false},"author":116983,"featured_media":59432,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"layout":"","cellInformation":"","apiCallInformation":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[2],"tags":[],"class_list":["post-68837","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","odd"],"acf":[],"yoast_head":"\nJoshua Zeidner, MD, Publishes "ENHANCE-2 Study" on Magrolimab and Azacitidine for TP53-Mutated AML. | Department of Medicine<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Joshua Zeidner, MD, Publishes "ENHANCE-2 Study" on Magrolimab and Azacitidine for TP53-Mutated AML. | Department of Medicine\" \/>\n<meta property=\"og:description\" content=\"Joshua Zeidner, MD, an Associate Professor of Medicine and Chief of Leukemia Research, published a paper in the journal Blood. Titled “Magrolimab plus azacitidine vs physician’s choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study,” he\u00a0looked at a global randomized phase 3 study in acute myeloid leukemia (AML). This study examined patients with TP53-mutated … Read more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/\" \/>\n<meta property=\"og:site_name\" content=\"Department of Medicine\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/UNCDeptMedicine\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-16T00:40:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-19T13:48:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Professional-Photo-with-White-Coat-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1858\" \/>\n\t<meta property=\"og:image:height\" content=\"2560\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Lillian Harbison\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@uncdeptmedicine\" \/>\n<meta name=\"twitter:site\" content=\"@uncdeptmedicine\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lillian Harbison\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/\"},\"author\":{\"name\":\"Lillian Harbison\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/583f230c1448c20a7f8507f25c34980c\"},\"headline\":\"Joshua Zeidner, MD, Publishes “ENHANCE-2 Study” on Magrolimab and Azacitidine for TP53-Mutated AML.\",\"datePublished\":\"2025-03-16T00:40:27+00:00\",\"dateModified\":\"2025-03-19T13:48:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/\"},\"wordCount\":326,\"image\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Professional-Photo-with-White-Coat-scaled.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/\",\"name\":\"Joshua Zeidner, MD, Publishes \\\"ENHANCE-2 Study\\\" on Magrolimab and Azacitidine for TP53-Mutated AML. | Department of Medicine\",\"isPartOf\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Professional-Photo-with-White-Coat-scaled.jpg\",\"datePublished\":\"2025-03-16T00:40:27+00:00\",\"dateModified\":\"2025-03-19T13:48:06+00:00\",\"author\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/583f230c1448c20a7f8507f25c34980c\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/#primaryimage\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Professional-Photo-with-White-Coat-scaled.jpg\",\"contentUrl\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Professional-Photo-with-White-Coat-scaled.jpg\",\"width\":1858,\"height\":2560,\"caption\":\"Joshua Zeidner, MD\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.med.unc.edu\/medicine\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Joshua Zeidner, MD, Publishes “ENHANCE-2 Study” on Magrolimab and Azacitidine for TP53-Mutated AML.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#website\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/\",\"name\":\"Department of Medicine\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.med.unc.edu\/medicine\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/583f230c1448c20a7f8507f25c34980c\",\"name\":\"Lillian Harbison\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/cf508b25f1a4b6cfd299cad04f9f23c1a5209708cf67893bec17599d8d00d461?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/cf508b25f1a4b6cfd299cad04f9f23c1a5209708cf67893bec17599d8d00d461?s=96&d=mm&r=g\",\"caption\":\"Lillian Harbison\"},\"url\":\"https:\/\/www.med.unc.edu\/medicine\/news\/author\/lilharbi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Joshua Zeidner, MD, Publishes \"ENHANCE-2 Study\" on Magrolimab and Azacitidine for TP53-Mutated AML. | Department of Medicine","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/","og_locale":"en_US","og_type":"article","og_title":"Joshua Zeidner, MD, Publishes \"ENHANCE-2 Study\" on Magrolimab and Azacitidine for TP53-Mutated AML. | Department of Medicine","og_description":"Joshua Zeidner, MD, an Associate Professor of Medicine and Chief of Leukemia Research, published a paper in the journal Blood. Titled “Magrolimab plus azacitidine vs physician’s choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study,” he\u00a0looked at a global randomized phase 3 study in acute myeloid leukemia (AML). This study examined patients with TP53-mutated … Read more","og_url":"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/","og_site_name":"Department of Medicine","article_publisher":"https:\/\/www.facebook.com\/UNCDeptMedicine","article_published_time":"2025-03-16T00:40:27+00:00","article_modified_time":"2025-03-19T13:48:06+00:00","og_image":[{"width":1858,"height":2560,"url":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Professional-Photo-with-White-Coat-scaled.jpg","type":"image\/jpeg"}],"author":"Lillian Harbison","twitter_card":"summary_large_image","twitter_creator":"@uncdeptmedicine","twitter_site":"@uncdeptmedicine","twitter_misc":{"Written by":"Lillian Harbison","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/#article","isPartOf":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/"},"author":{"name":"Lillian Harbison","@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/583f230c1448c20a7f8507f25c34980c"},"headline":"Joshua Zeidner, MD, Publishes “ENHANCE-2 Study” on Magrolimab and Azacitidine for TP53-Mutated AML.","datePublished":"2025-03-16T00:40:27+00:00","dateModified":"2025-03-19T13:48:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/"},"wordCount":326,"image":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/#primaryimage"},"thumbnailUrl":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Professional-Photo-with-White-Coat-scaled.jpg","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/","url":"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/","name":"Joshua Zeidner, MD, Publishes \"ENHANCE-2 Study\" on Magrolimab and Azacitidine for TP53-Mutated AML. | Department of Medicine","isPartOf":{"@id":"https:\/\/www.med.unc.edu\/medicine\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/#primaryimage"},"image":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/#primaryimage"},"thumbnailUrl":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Professional-Photo-with-White-Coat-scaled.jpg","datePublished":"2025-03-16T00:40:27+00:00","dateModified":"2025-03-19T13:48:06+00:00","author":{"@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/583f230c1448c20a7f8507f25c34980c"},"breadcrumb":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/#primaryimage","url":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Professional-Photo-with-White-Coat-scaled.jpg","contentUrl":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Professional-Photo-with-White-Coat-scaled.jpg","width":1858,"height":2560,"caption":"Joshua Zeidner, MD"},{"@type":"BreadcrumbList","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/joshua-zeidner-md-publishes-enhance-2-study-on-magrolimab-and-azacitidine-for-tp53-mutated-aml\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.med.unc.edu\/medicine\/"},{"@type":"ListItem","position":2,"name":"Joshua Zeidner, MD, Publishes “ENHANCE-2 Study” on Magrolimab and Azacitidine for TP53-Mutated AML."}]},{"@type":"WebSite","@id":"https:\/\/www.med.unc.edu\/medicine\/#website","url":"https:\/\/www.med.unc.edu\/medicine\/","name":"Department of Medicine","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.med.unc.edu\/medicine\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/583f230c1448c20a7f8507f25c34980c","name":"Lillian Harbison","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/cf508b25f1a4b6cfd299cad04f9f23c1a5209708cf67893bec17599d8d00d461?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/cf508b25f1a4b6cfd299cad04f9f23c1a5209708cf67893bec17599d8d00d461?s=96&d=mm&r=g","caption":"Lillian Harbison"},"url":"https:\/\/www.med.unc.edu\/medicine\/news\/author\/lilharbi\/"}]}},"featured_image":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Professional-Photo-with-White-Coat-scaled.jpg","featured_image_medium":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Professional-Photo-with-White-Coat-218x300.jpg","featured_image_medium_large":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Professional-Photo-with-White-Coat-768x1058.jpg","featured_image_large":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Professional-Photo-with-White-Coat-743x1024.jpg","featured_image_thumbnail":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2019\/03\/Zeidner-Professional-Photo-with-White-Coat-150x150.jpg","featured_image_alt":"Zeidner-Professional-Photo-with-White-Coat","category_details":[{"name":"News","link":"https:\/\/www.med.unc.edu\/medicine\/news\/category\/news\/"}],"tag_details":[],"_links_to":[],"_links_to_target":[],"_links":{"self":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/posts\/68837","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/users\/116983"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/comments?post=68837"}],"version-history":[{"count":0,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/posts\/68837\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/media\/59432"}],"wp:attachment":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/media?parent=68837"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/categories?post=68837"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/tags?post=68837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}